Last month (May 2025), Novo Nordisk and Septerna, a San Francisco, California-based bio/pharmaceutical company focused on GCPRs, formed an exclusive global collaboration and license agreement to discover, develop, and commercialize oral small-molecule medicines for treating obesity, Type 2 diabetes, and other cardiometabolic diseases, in a deal worth up to $2.2 billion ($200 million upfront and near-term funding and $2 billion in milestone payments)
When their levels shift significantly, as in pregnancy, with the use or cessation of oral contraceptives, or during perimenopause, melanocytes in hormonally sensitive perioral zones can substantially increase melanin output
Please note that if you disable cookies on your Internet-enabled device, some parts of the Services may not function properly or offer you the same degree of personalization
Wickham S, West MB, Cook PF, Hanigan MH
That's because you're engaging muscles, breathing heavily and actively moving, which promotes healthy blood sugar levels, encourages healthy insulin sensitivity, helps manage a healthy weight and much more
Frye, R